celecoxib

Celecoxib (SC 58635) 是一种非甾体抗炎剂，是 一种 COX-2 抑制剂 (IC50=40 nM)，具有选择性。Celecoxib 具有抗炎和止痛活性，可以用于治疗骨关节炎、类风湿性关节炎、急性疼痛等。

Celecoxib carboxylic acid is an inactive metabolite of the COX-2 inhibitor celecoxib .1,2It is formed from celecoxib primarily by the cytochrome P450 (CYP) isoform CYP2C9. 1.Liu, H., Huang, X., Shen, J., et al.Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: Molecular docking and 3D QSAR analysesJ. Med. Chem.45(22)4816-4827(2002) 2.Kim, S.-H., Kim, D.-H., Byeon, J.-Y., et al.Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metaboliteArch. Pharm. Res.40(3)382-390(2017)

Celecoxib carboxylic acid acyl-β-D-glucuronide is a phase II metabolite of celecoxib . Celecoxib is an anti-inflammatory compound from the diaryl heterocycle class that selectively inhibits cyclooxygenase-2 (COX-2; IC50s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively). Celecoxib carboxylic acid acyl-β-D-glucuronide is a minor metabolite, accounting for 2% of the administered dose in human urine and rat bile.

Hydroxy celecoxib, an inactive metabolite of celecoxib, is synthesized through the metabolism of celecoxib by cytochrome P450 (CYP) isoforms CYP2C9, CYP3A4, and CYP2D6 in human liver microsomes.

Desmethyl Celecoxib 是一种选择性的环氧化酶 2 (COX-2) 抑制剂，IC50为 32 nM，具有抗炎活性。

2,5-dimethyl Celecoxib 是塞来昔布衍生物和微粒体前列腺素 E 合酶 1 (mPGES-1) 的靶向抑制剂，mPGES-1 是炎症介质 PGE2 合成途径中的关键酶。

Osu03012 (AR-12) 是一种口服生物可利用的小分子塞来昔布衍生的磷酸肌醇依赖性激酶 1(PDK1) 抑制剂，具有潜在的抗肿瘤活性。

Parecoxib is a cyclooxygenase-2 inhibitor used for the short-term treatment of postoperative pain in adults. Parecoxib is a water-soluble and injectable prodrug of valdecoxib. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib and r

COX-2-IN-7 (compound 4a) 是口服有效的COX-2 选择性抑制剂，其选择性高于 Celecoxib，IC50值为6.585 uM。COX-2-IN-7 在体内具有良好的抗炎和低致溃疡活性。

COX-2 5-LOX-IN-1 (compound 3a), a benzothiophen-2-yl pyrazole carboxylic acid derivative, is a potent and dual inhibitor of COX-2 5-LOX. It exhibits superior analgesic and anti-inflammatory properties compared to Celecoxib and Indomethacin. COX-2 5-LOX-IN-1 displays strong inhibitory activity against COX-1, COX-2, and 5-LOX, with IC50 values of 12.13 μM, 0.4 μM, and 4.96 μM, respectively [1].

COX-2-IN-18 (Compound 3) is a highly effective COX-2 inhibitor with strong inhibitory activity against COX-2 (IC 50 = 0.775 μM). Its potency is comparable to the reference drug Celecoxib (IC 50 = 0.153 μM). This compound, COX-2-IN-18, shows promise in the field of cancer research [1].

COX-2 5-LOX-IN-2 是苯并噻吩-2-基吡唑羧酸衍生物。COX-2 5-LOX-IN-2 (5b) 对COX-2和5-LOX 均有抑制作用。COX-2 5-LOX-IN-2 抑制 COX-1、COX-2 和 5-LOX 的IC50s 分别为 5.40、0.01 和 1.78 μM。COX-2 5-LOX-IN-2 显示出超过塞来昔布和吲哚美辛的镇痛和抗炎活性。

COX-2-IN-8 (compound 6a) 是一种有效的、选择性的、口服具有活力的 COX-2 抑制剂 (IC50: 6.585 μM)。COX-2-IN-8 的 COX-2 选择性比 Celecoxib 高。COX-2-IN-8 在体内表现出良好的抗炎活性和低致溃疡效果。

COX-2-IN-9 是选择性的、有效的、口服具有活力的 COX-2 抑制剂 (IC50: 10.17 μM)。COX-2-IN-9 的 COX-2 选择性比 Celecoxib 高。COX-2-IN-9 表现出良好的体内抗炎活性和低致溃疡效果。

R-130823 is a ighly selective inhibition against mitogen-activated protein kinase p38alpha (IC50=22 nM). The release of tumor necrosis factor-alpha, interleukin-1beta, -6 and -8 was inhibited in lipopolysaccharide-stimulated human blood pretreated by R-130823 , with IC50 values of 0.089, 0.066, 0.95 and 0.16 microM, respectively. R-130823 reduced the established hind paw swelling in rat adjuvant-induced arthritis, while methotrexate showed no suppression. In the same model, R-130823 ameliorated adjuvant-induced hyperalgesia with rapid onset and long duration comparable to a cyclooxygenase-2 inhibitor, celecoxib.

COX-1 2-IN-8 (compound 11f) 作为一种具有口服有效性的COX-1和COX-2抑制剂,其对COX-1和COX-2的IC50值分别是2.14 µM和0.58 µM.此外,该化合物在抗炎活性方面优于塞来昔布.